Rational Design of an Improved Tissue-engineered Vascular Graft: Determining the Optimal Cell Dose and Incubation Time

Overview

Journal Regen Med

Specialty Biotechnology

Date 2016 Mar 2

PMID 26925512

Citations 20

Authors

Yong-Ung Lee

Nathan Mahler

Cameron A Best

Shuhei Tara

Tadahisa Sugiura

Avione Y Lee

Tai Yi

Narutoshi Hibino

Toshiharu Shinoka

Christopher Breuer

Affiliations

Soon will be listed here.

Abstract

Aim: We investigated the effect of cell seeding dose and incubation time on tissue-engineered vascular graft (TEVG) patency.

Materials & Methods: Various doses of bone marrow-derived mononuclear cells (BM-MNCs) were seeded onto TEVGs, incubated for 0 or 12 h, and implanted in C57BL/6 mice. Different doses of human BM-MNCs were seeded onto TEVGs and measured for cell attachment.

Results: The incubation time showed no significant effect on TEVG patency. However, TEVG patency was significantly increased in a dose-dependent manner. In the human graft, more bone marrow used for seeding resulted in increased cell attachment in a dose-dependent manner.

Conclusion: Increasing the BM-MNC dose and reducing incubation time is a viable strategy for improving the performance and utility of the graft.

Citing Articles

Tissue Engineering of Vascular Grafts: A Case Report From Bench to Bedside and Back.

Breuer T, Jimenez M, Humphrey J, Shinoka T, Breuer C Arterioscler Thromb Vasc Biol. 2023; 43(3):399-409.

PMID: 36633008 PMC: 9974789. DOI: 10.1161/ATVBAHA.122.318236.

Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth.

Blum K, Zbinden J, Ramachandra A, Lindsey S, Szafron J, Reinhardt J Commun Med (Lond). 2022; 2:3.

PMID: 35603301 PMC: 9053249. DOI: 10.1038/s43856-021-00063-7.

Current Progress in Vascular Engineering and Its Clinical Applications.

Jouda H, Larrea Murillo L, Wang T Cells. 2022; 11(3).

PMID: 35159302 PMC: 8834640. DOI: 10.3390/cells11030493.

CCL2 loaded microparticles promote acute patency in silk-based vascular grafts implanted in rat aortae.

Lorentz K, Gupta P, Shehabeldin M, Cunnane E, Ramaswamy A, Verdelis K Acta Biomater. 2021; 135:126-138.

PMID: 34496284 PMC: 8595801. DOI: 10.1016/j.actbio.2021.08.049.

Review on Mechanical Support and Cell-Based Therapies for the Prevention and Recovery of the Failed Fontan-Kreutzer Circulation.

Ferrari M, Di Maria M, Jacot J Front Pediatr. 2021; 8:627660.

PMID: 33575233 PMC: 7870783. DOI: 10.3389/fped.2020.627660.

References

Roh J, Sawh-Martinez R, Brennan M, Jay S, Devine L, Rao D . Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A. 2010; 107(10):4669-74. PMC: 2842056. DOI: 10.1073/pnas.0911465107. View

BLAKEMORE A, VOORHEES Jr A . The use of tubes constructed from vinyon N cloth in bridging arterial defects; experimental and clinical. Ann Surg. 1954; 140(3):324-34. PMC: 1609759. DOI: 10.1097/00000658-195409000-00008. View

Shinoka T, Shum-Tim D, Ma P, Tanel R, Isogai N, Langer R . Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg. 1998; 115(3):536-45; discussion 545-6. DOI: 10.1016/S0022-5223(98)70315-0. View

Udelsman B, Hibino N, Villalona G, McGillicuddy E, Nieponice A, Sakamoto Y . Development of an operator-independent method for seeding tissue-engineered vascular grafts. Tissue Eng Part C Methods. 2011; 17(7):731-6. PMC: 3124112. DOI: 10.1089/ten.TEC.2010.0581. View

Weinberg C, Bell E . A blood vessel model constructed from collagen and cultured vascular cells. Science. 1986; 231(4736):397-400. DOI: 10.1126/science.2934816. View

Fernandez C, Achneck H, Reichert W, Truskey G . Biological and engineering design considerations for vascular tissue engineered blood vessels (TEBVs). Curr Opin Chem Eng. 2014; 3:83-90. PMC: 3915872. DOI: 10.1016/j.coche.2013.12.001. View

Shinoka T, Matsumura G, Hibino N, Naito Y, Watanabe M, Konuma T . Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg. 2005; 129(6):1330-8. DOI: 10.1016/j.jtcvs.2004.12.047. View

Hibino N, Yi T, Duncan D, Rathore A, Dean E, Naito Y . A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J. 2011; 25(12):4253-63. PMC: 3236622. DOI: 10.1096/fj.11-186585. View

Brennan M, Dardik A, Hibino N, Roh J, Nelson G, Papademitris X . Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann Surg. 2008; 248(3):370-7. PMC: 2726802. DOI: 10.1097/SLA.0b013e318184dcbd. View

10.

Kurobe H, Maxfield M, Naito Y, Cleary M, Stacy M, Solomon D . Comparison of a closed system to a standard open technique for preparing tissue-engineered vascular grafts. Tissue Eng Part C Methods. 2014; 21(1):88-93. PMC: 4291206. DOI: 10.1089/ten.TEC.2014.0160. View

11.

McAllister T, Maruszewski M, Garrido S, Wystrychowski W, Dusserre N, Marini A . Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet. 2009; 373(9673):1440-6. DOI: 10.1016/S0140-6736(09)60248-8. View

12.

Kurobe H, Tara S, Maxfield M, Rocco K, Bagi P, Yi T . Comparison of the biological equivalence of two methods for isolating bone marrow mononuclear cells for fabricating tissue-engineered vascular grafts. Tissue Eng Part C Methods. 2014; 21(6):597-604. PMC: 4442596. DOI: 10.1089/ten.TEC.2014.0442. View

13.

Roh J, Nelson G, Brennan M, Mirensky T, Yi T, Hazlett T . Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials. 2008; 29(10):1454-63. PMC: 2375856. DOI: 10.1016/j.biomaterials.2007.11.041. View

14.

Lee Y, Yi T, Tara S, Lee A, Hibino N, Shinoka T . Implantation of inferior vena cava interposition graft in mouse model. J Vis Exp. 2014; (88). PMC: 4186658. DOI: 10.3791/51632. View

15.

Shinoka T, Imai Y, Ikada Y . Transplantation of a tissue-engineered pulmonary artery. N Engl J Med. 2001; 344(7):532-3. DOI: 10.1056/NEJM200102153440717. View

16.

Duncan D, Chen P, Patterson J, Lee Y, Hibino N, Cleary M . TGFβR1 inhibition blocks the formation of stenosis in tissue-engineered vascular grafts. J Am Coll Cardiol. 2015; 65(5):512-4. PMC: 9743980. DOI: 10.1016/j.jacc.2014.08.057. View

17.

Hibino N, McGillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C . Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010; 139(2):431-6, 436.e1-2. DOI: 10.1016/j.jtcvs.2009.09.057. View

18.

Bowald S, Busch C, Eriksson I . Arterial regeneration following polyglactin 910 suture mesh grafting. Surgery. 1979; 86(5):722-9. View

19.

Vacanti J, Morse M, Saltzman W, Domb A, Langer R . Selective cell transplantation using bioabsorbable artificial polymers as matrices. J Pediatr Surg. 1988; 23(1 Pt 2):3-9. DOI: 10.1016/s0022-3468(88)80529-3. View

20.

Patterson J, Gilliland T, Maxfield M, Church S, Naito Y, Shinoka T . Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again. Regen Med. 2012; 7(3):409-19. PMC: 3384697. DOI: 10.2217/rme.12.12. View